Abstract
Psoriasis is a systemic inflammatory disease with manifestation on the skin. Psoriasis is in majority of patients associated with various comorbidities, especially obesity, metabolic syndrome, osteoporosis and migraine.
These comorbidities are also characterised by the presence of harm inflammation. Therapeutic control of comorbidities can positively impacts also the activity of psoriasis.
The most effective treatment of dyslipidemia is based on the administration of biologics targeting PCSK-9 molecule. This molecule is also directly involved in immunopathological processes characterising psoriasis.
Neuroinflammation, which is an integral part of pathophysiology migraine is efficiently treated by biologics targeting CGRP molecule. This molecule is also participating on immunopathogenesis of psoriasis.
It could be possible to anticipate that in near future universal targets common for harm inflammation responsible for both psoriasis and comorbidities will be identified and targeted by specific therapies.